Scios
As of the edition of 20 October 2026, Scios runs 2 drugs, 1 of them marketed; it is on route A at 1 target and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Scios was merged in 1995.
- Scios, Inc.: merged in 1995
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Total | 2 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Nesiritide | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 1 target.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Scios needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Heart and blood vessels: 14 trials led
- Pregnancy and women's health: 8 trials led
- Urinary and reproductive: 8 trials led